- You are here
With the RIVAR project, we offer vulnerable infants added protection against stomach flu and diarrhea. RIVAR is the acronym of Risk-group Infant Vaccination Against Rotavirus. The rotavirus is a key cause of stomach flu and diarrhea in infants and toddlers. Babies who are born prematurely or too small, or infants with a congenital condition of, for example, the heart or intestines, are particularly vulnerable to this virus.
With the RIVAR project, we offer vulnerable infants added protection against stomach flu and diarrhea. RIVAR is the acronym of Risk-group Infant Vaccination Against Rotavirus. The rotavirus is a key cause of stomach flu and diarrhea in infants and toddlers. Babies who are born prematurely or too small, or infants with a congenital condition of, for example, the heart or intestines, are particularly vulnerable to this virus. Rotavirus vaccination protects babies against this. Vulnerable infants in particular benefit from this vaccination. Rotavirus infection of these vulnerable infants is often more serious and lasts longer than in healthy babies. As part of the RIVAR project, vulnerable infants are offered the rotavirus vaccination in the hospital where they are treated. The pediatrician determines which babies qualify, based on a number of standard criteria.
Rotavirus vaccines have been available for about ten years now. In many countries, this vaccination is standard for infants to protect them against stomach flu and diarrhea.
In the Netherlands, rotavirus vaccination is still fairly unknown and hardly ever used. It is an oral vaccine. This means that infants are not given an injection, but are administered drops in the mouth. They are given their first dose of rotavirus vaccine when they are about eight weeks old. This can be done - but not necessarily so - together with the other vaccinations in the national vaccination program. They are given the second dose when they are three of four months old. Sometimes, a third dose may be necessary, which is given one to two months after the second dose.
What results does the RIVAR project have?
The RIVAR project is a trial period for nation-wide introduction of rotavirus vaccination of vulnerable infants. The experiences of the twelve pilot hospitals with the RIVAR program help us determine how to optimize vaccination efficiency. On the other hand, the RIVAR project also produces a lot of knowledge about the effectiveness of rotavirus vaccination, specifically in vulnerable infants. And, for example, whether the dosing schedule must be adjusted.
The RIVAR project is funded by a grant from the Netherlands Organisation for Health Research and Development (ZonMw, project number 80-83600-98-20129, Proper Use of Medicines program), the Innovatiefonds Zorgverzekeraars, and UMC Utrecht. GlaxoSmithKline produces and supplies the required rotavirus vaccines for hospitals that participate in the RIVAR project. Parents/guardians of vulnerable infants do not have to pay anything for participation in the RIVAR project.
For questions about the RIVAR project, which vulnerable infants are eligible or which hospitals participate, you can send an email to: firstname.lastname@example.org
Email us if you have any questions about the RIVAR project, which vulnerable infants are eligible or which hospitals participate: email@example.com